

ELC ENHANCING DETECTION: HAWAII TESTING PLAN

2020 Overarching Jurisdictional SARS-COV-2 Testing Strategy

Jurisdiction:	Hawaii
Population Size:	1,416,000

1. Describe the overarching testing strategy in your state or jurisdiction.

a) The State Laboratories Division (SLD) has received 15 Abbott IDNow instruments, which have been distributed to eight laboratories which were not previously conducting molecular COVID testing. SLD currently receives 50 test kits (1,200 tests) per week, which are distributed to laboratories which have the instruments we provided. SLD is also adding new high throughput instrumentation (Hologic Panther and ThermoFisher), enabling a several-fold increase in testing capacity. SLD periodically surveys COVID testing laboratories for testing capacities, workforce status, supplies inventories, workload numbers, turnaround times, and related information. Survey results are shared with Hawaii Department of Health (HDOH) stakeholders and Federal partners.

b) The Hawaii Department of Health (HDOH) is engaging a number of partners in long-term care facilities, correctional facilities, homeless programs, universities, etc. to establish active surveillance programs to regularly screen persons for symptoms and recommend COVID testing at a low threshold (e.g., only one of the following present: subjective fever, chills, cough, or sore throat; or for certain populations such as elderly, altered mentation or acute change in activities of daily living). Specimens from such persons would be directed to SLD for both COVID-19 and respiratory pathogen panel (RPP) testing to allow monitoring of all potential respiratory pathogens and gain an understanding of their activity and trends in relation to each other. We are also reaching out to those with appropriate clinical support (e.g., advanced practice nurses in pharmacy clinics, homecare agencies) to explore potential collaborations to provide testing referral support to our Sentinel Surveillance Providers. Additionally, we are working toward establishing "swab teams" to provide testing referral support for both Sentinel Providers and investigation purposes.

c) When serological assay capacity is established at the State Laboratories Division (SLD), we plan to launch a statewide serological survey that will likely involve a partnership primarily with our Sentinel Providers and potentially other similar partners to identify persons from across the state for inclusion. As we are aggressively recruiting new Sentinel Providers especially from among the federally qualified health centers and other community clinics, we anticipate representation from multiple rural and cultural communities. Additionally, we are considering a serosurvey that may target the pediatric population to better understand the role of children in COVID-19 disease activity.

d) SLD already periodically surveys COVID testing laboratories for testing capacities, workforce status, supplies inventories, workload numbers, turnaround times, and related information and will continue to do so. Survey results are shared with Hawaii Department of Health (HDOH) stakeholders and Federal partners.

ELC ENHANCING DETECTION: HAWAII TESTING PLAN

Table #1a: Number of individuals planned to be tested, by month

BY MONTH:	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20	TOTAL
Diagnostics*	15,200	10,000							25,200
Serology	8,700	10,000							18,700
TOTAL	23,900	20,000	0	0	0	0	0	0	

Table #1b: Planned expansion of testing jurisdiction-wide

Name of testing entity	Testing venue (select from drop down)	Performing Lab (if different from testing entity)	Daily diagnostic throughput	Daily serologic throughput	Platforms or devices used (list all)	Specific at-risk populations targeted (list all)
State Labs Division	Public health lab		20	0		Symptomatic and at-risk patients
Diagnostic Lab Services	Commercial or private lab		200	19		Symptomatic and at-risk patients
Clin Labs of Hawaii	Commercial or private lab		185	287		Symptomatic and at-risk patients

ELC ENHANCING DETECTION: HAWAII TESTING PLAN

Name of testing entity	Testing venue (select from drop down)	Performing Lab (if different from testing entity)	Daily diagnostic throughput	Daily serologic throughput	Platforms or devices used (list all)	Specific at-risk populations targeted (list all)
Kaiser	Hospitals or clinical facility		54	19		Symptomatic and at-risk patients
Adventist Castle	Hospitals or clinical facility		40	0		Symptomatic and at-risk patients
S & G Laboratories	Commercial or private lab		100	0		Symptomatic and at-risk patients

2020 Direct Expansion of SARS-COV-2 Testing by Health Departments

2. Describe your public health department's direct impact on testing expansion in your jurisdiction.

a) The State Laboratories Division (SLD) has received 15 Abbott IDNow instruments, which have been distributed to eight laboratories which were not previously conducting molecular COVID testing. SLD currently receives 50 test kits (1,200 tests) per week, which are distributed to laboratories which have the instruments we provided. SLD is also adding new high throughput instrumentation (Hologic Panther and ThermoFisher), enabling a several-fold increase in testing capacity. SLD periodically surveys COVID testing laboratories for testing capacities, workforce status, supplies inventories, workload numbers, turnaround times, and related information. Survey results are shared with Hawaii Department of Health (HDOH) stakeholders and Federal partners.

b) Among the laboratories acquiring the IDNow instruments are District Health Laboratories in neighbor islands where testing was not previously available. This added new capability for underserved communities. To date Hawaii has not had an outbreak in a nursing home or long-term care facility. Swab teams and testing capacity are available should one occur. Additionally, DOH is working with partners in long-term care facilities and correctional facilities as well as those working with the homeless to provide technical assistance for ensuring infection control measures, establish active surveillance for COVID-19 with a low threshold for testing suspect cases at SLD, and implement a protocol to test all persons epidemiologically linked to a confirmed case.

c) Public and private sector laboratories at present have sufficient inventory to perform more than 38,000 molecular tests for the presence of SARS-CoV-2. Testing reagents are ordered from a variety of manufacturers, assuring a diversity of supply chain and making stock-outs less likely. The Office of Public Health Preparedness has in stock more than 30,000 collection kits including viral transport medium and collection swabs. We recognize, however, that healthcare providers may continue to be challenged in assuring their PPE supply to test patients. Therefore, in the interim we have established "swab team" support in collaboration with the Hawaii National Guard. Using ELC Enhanced Detection funds, we plan to establish permanent swab teams, which will also support community outreach activities especially to support education of racial and ethnic minorities. Additionally, we are reaching out to other partners with appropriate clinical support (e.g., advanced practice nurses in pharmacy clinics or home care agencies) with the plan to further establish a referral network for providers to refer patients for testing.

d) SLD is evaluating Roche, Ortho, and Abbott testing platforms. All are high-throughput platforms. We expect to initiate a purchase order by June 15. In anticipation, the Disease Outbreak Control Division (DOCD [Epi]) is developing a serosurvey protocol that will likely involve a collaboration with our Sentinel Surveillance Providers and other similar clinical partners to identify persons from across the state to be included in the serosurvey. We are also considering a separate protocol that may specifically target the pediatric population.

e) HDOH has a sentinel surveillance program based on the flu/ILI surveillance framework with collaborating healthcare providers. HDOH is aggressively recruiting more providers, especially federally qualified health centers and other community health clinics to ensure inclusion of rural and other vulnerable populations in our community. Testing of symptomatic patients (at least fever, chills, new

ELC ENHANCING DETECTION: HAWAII TESTING PLAN

onset cough, or sore throat) is provided without charge by SLD. Active surveillance is also planned for nursing home/long term care facilities in all four counties, as noted above in b).

f) New key staff positions have been requested of the CDC Foundation to support recruiting and hiring positions, as this method seemed to be the most rapid means to do so. We will evaluate other key positions and will likely work to establish some positions through the regular State process for establishing exempt positions under a new special project, while we recruit and hire others via a contractor agency or the University of Hawaii , which may act as a 3rd party similar to the CDC Foundation to more quickly recruit and hire positions. DOH's Office of Public Health Preparedness has taken the lead in assuring specimen collection materials are available in the State. Swabs and viral transport media have been procured and are being distributed to public health laboratories and, when shortages occur, to private sector laboratories.

ELC ENHANCING DETECTION: HAWAII TESTING PLAN

Table #2: Planned expansion of testing driven by public health departments

BY MONTH:	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20	TOTAL
Number of additional* staff to meet planned testing levels	0	2							2
FOR DIAGNOSTIC TESTING									
How many additional* testing equipment/devices are needed to meet planned testing levels? (provide an estimated number, and include platform details in narrative above)	0	1							1
Volume of additional swabs needed to meet planned testing levels ⁺⁺	0	10,000							10,000
Volume of additional media (VTM, MTM, saline, etc.) needed to meet planned testing levels ⁺⁺	0	10,000							10,000
Volume of additional reagents needed to meet planned testing levels, by testing unit and platform (i.e. 100K/day - Hologic panther; 100k/day - Thermofisher)		5000 HolPnth 5000 ThrmFsh							10,000
FOR SEROLOGIC TESTING									
Number of additional* equipment and devices to meet planned testing levels	0	2							2

ELC ENHANCING DETECTION: HAWAII TESTING PLAN

BY MONTH:	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20	TOTAL
Volume of additional reagents needed to meet planned testing levels, by testing unit and platform (i.e. 100K/day - Hologic panther; 100k/day - Thermofisher)		10,000 Roche							10,000

* Report new monthly additions only, not cumulative levels

++ For May and June, only include needs beyond the supplies provided by FEMA. Report new monthly additions only, not cumulative levels.